Breakthroughs in IgA Nephropathy and Kidney Care Dominate November 2025
A surge of positive clinical trial data and regulatory approvals marked November 2025 as a pivotal month for nephrology, particularly in the treatment of IgA nephropathy (IgAN). From presentations at the American Society of Nephrology (ASN) Kidney Week 2025 to decisions from the US Food and Drug Administration (FDA), significant advancements are reshaping the landscape of kidney care and offering new hope for patients.
A Rapidly Evolving Therapeutic Landscape
November’s developments underscore the accelerating pace of innovation in kidney therapeutics and clinical management. Progress extends beyond IgAN, with promising results emerging in focal segmental glomerulosclerosis (FSGS) and membranous nephropathy, as well as advancements in kidney transplantation and the management of chronic kidney disease (CKD). These breakthroughs are poised to improve remission rates, long-term outcomes, and the overall quality of life for individuals affected by kidney disorders.
FDA Greenlights Sibeprenlimab for IgAN
In a landmark decision, the FDA granted accelerated approval to sibeprenlimab (Voyxact), a targeted APRIL inhibitor, for adults with IgAN at risk of disease progression. Data from the phase 3 VISIONARY trial demonstrated a compelling safety profile and a substantial 54.3% reduction in proteinuria, alongside improvements in key disease biomarkers like galactose-deficient immunoglobulin A1 (Gd-IgA1). “This approval represents a significant step forward in providing a new treatment option for patients facing the challenges of progressive kidney disease due to IgAN,” according to a company release.
Telitacicept Demonstrates Strong Efficacy in Phase 3 Trial
Further bolstering the positive momentum, the B-cell modulating biologic telitacicept successfully met its primary endpoint in a phase 3 study. Investigators reported a remarkable -58.9% change in 24-hour urine protein-to-creatinine ratio (24h-UPCR) compared to -8.8% for placebo (P < .0001). The favorable safety profile observed in the trial further supports telitacicept’s potential as a disease-modifying therapy for high-risk IgAN patients.
Atacicept Data Presented at ASN Kidney Week 2025
Interim results from the ORIGIN-3 trial, unveiled at ASN Kidney Week 2025, highlighted the efficacy of the dual BAFF/APRIL inhibitor atacicept. The data revealed a 68.3% decrease in Gd-IgA1, resolution of dipstick hematuria in 81.0% of patients, and a 47.3% reduction in urinary albumin-to-creatinine ratio. Jonathan Barratt, MBChB, PhD, provided valuable insights into atacicept’s role in the evolving IgAN pathway, emphasizing its potential to address the underlying immunological drivers of the disease.
Expanding Horizons in Kidney Care
Beyond IgAN, November 2025 saw continued progress across the spectrum of kidney disease. Advancements in kidney transplantation, including safer rejection prevention strategies with tegoprubart, and supportive data regarding post-transplant pregnancies, offer actionable insights for clinicians. Furthermore, developments in CKD, dialysis, and rare kidney disorders, including new FDA orphan designations and late-stage trial readouts, are continually expanding the therapeutic landscape and informing evidence-based care.
The rapid advancements witnessed this month signal a new era of hope and innovation for individuals living with kidney disease, promising improved outcomes and a better quality of life.
